HIV/AIDS Clinical Care: Archives

SUMMARY AND COMMENT

Rosuvastatin Beats Pravastatin for PI-Associated Hyperlipidemia

• November 16, 2009
• Abigail Zuger, MD

However, the study was small, and patients were followed for only 45 days.

• Reviewing:
• Aslangul E et al., AIDS 2009 Oct 15

SUMMARY AND COMMENT

hsCRP Levels and CVD Risk Factors in Patients on ARTFree

• November 16, 2009
• Keith Henry, MD

In a cohort of patients with virologic suppression and low estimated cardiovascular risk, hsCRP levels were elevated and were associated with increased BMI and lipid abnormalities.

• Reviewing:
• Boger MS et al., J Acquir Immune Defic Syndr 2009 Dec; 52:480

SUMMARY AND COMMENT

Immune Activation Persists Despite Effective ARTFree

• November 9, 2009
• Helmut Albrecht, MD

In a cohort of HIV-positive patients, markers of immune activation remained elevated despite 6 years of effective antiretroviral therapy. Immune activation was associated with lower CD4-cell counts.

• Reviewing:
• French MA et al., J Infect Dis 2009 Oct 15; 200:1212

SUMMARY AND COMMENT

Second-Regimen Failure and Mortality Risk

• November 9, 2009
• Keith Henry, MD

Although second-regimen failure and associated mortality declined significantly between 1996/1997 and 2005, the mortality risk remained high.

• Reviewing:
• Deeks SG et al., Clin Infect Dis 2009 Nov 15; 49:1582

SUMMARY AND COMMENT

Influence of HCV Infection on Mortality in HIV-Infected Patients

• November 9, 2009
• Rajesh T. Gandhi, MD

HCV infection is associated with increased overall mortality, but not with AIDS-defining events, in HIV-infected patients.

• Reviewing:
• Chen T-Y et al., Clin Infect Dis 2009 Nov 15; 49:1605

SUMMARY AND COMMENT

No Increase in Transmitted HIV-Drug Resistance in Europe

• November 2, 2009
• Charles B. Hicks, MD

Between 2002 and 2006, the rates of transmitted drug resistance in Europe stabilized at <10%. Possible reasons abound.

• Reviewing:
• Vercauteren J et al., J Infect Dis 2009 Nov 15; 200:1503

SUMMARY AND COMMENT

Life Expectancy for HIV-Infected Patients in the U.S.

• November 2, 2009
• Sonia Nagy Chimienti, MD

Average life expectancy continues to improve, but disparities persist.

• Reviewing:
• Harrison KM et al., J Acquir Immune Defic Syndr 2009 Sep 2

SUMMARY AND COMMENT

Dose Reduction Curbs Efavirenz Toxicity

• November 2, 2009
• Abigail Zuger, MD

Reducing the daily dose of efavirenz to 400 mg or even lower may curb the drug's toxicity without decreasing its effectiveness in patients with high plasma levels.

• Reviewing:
• van Luin M et al., J Acquir Immune Defic Syndr 2009 Oct 1; 52:240

SUMMARY AND COMMENT

Darunavir + Raltegravir + Etravirine = High Rate of Treatment Success

• November 2, 2009
• Paul E. Sax, MD

Ninety percent of highly treatment-experienced patients who received this combination achieved virologic suppression at week 24; results were sustained at week 48.

• Reviewing:
• Yazdanpanah Y et al., Clin Infect Dis 2009 Nov 1; 49:1441

NEWS IN CONTEXT

New CDC Interim Guidance on HIV and H1N1Free

• November 2, 2009
• Carlos del Rio, MD

HIV-infected individuals are a high-priority group for prevention and treatment of 2009 H1N1 influenza.

• Reviewing:
• Centers for Disease Control and Prevention (CDC)., 2009 Oct 21